Genoa Ventures invests in early-stage companies innovating at the convergence of biology and technology. 

Visionary startups developing innovative life science technologies with outsized potential often struggle to raise capital from traditional funders. These companies are typically multi-disciplinary (e.g. genomics + optics + microfluidics + big data) and/or market-making, and don't neatly fit most VC’s patterns and boxes.

Genoa Ventures stands in this gap. Genoa Ventures uniquely combines an appetite for technology-driven, “category-defying” opportunities in life sciences with the domain expertise and operational experience necessary to select and nurture the best bio-based companies early, before most other investors. We take the time to understand the science and technology, applications and markets, and to help these companies achieve their full potential.

We believe in the enormous and relatively untapped possibilities of life science technologies and discoveries applied to realms outside of healthcare, and in the unbounded potential of the entrepreneurial visionaries who will lead us in realizing these possibilities.

Intabio

Zephyrus Biosciences

Zymergen

Caribou Biosciences

Genoa Ventures

Great science can form the foundation for a world-changing company. But innovative and transformative ideas require significant vision, work, investment, and perseverance to move out of the lab and into the market.

In our new video series, 2022 Chemistry Nobel Laureate Carolyn Bertozzi Ph.D., joins Genoa Ventures Founder and Managing Director Jenny Rooke Ph.D., to discuss how to translate scientific developments and academic research into blockbuster businesses. They revisit the inception of their collaboration and how the intersection of interdisciplinary innovations led to Dr. Bertozzi’s founding of numerous start-up, including Genoa’s portfolio company InterVenn Biosciences.

Watch the full length video here: https://lnkd.in/eRdRn6bc

#nobellaureate #venturecapital #genoaportco #biotech #datascience

Genoa Venture Partner William (Bill) Hyun, PhD, participated in a panel at #AACR2024 this weekend, discussing the Road to Entrepreneurship and how early-stage companies can find investors. 

Bill has been a founder, investor, and advisor to over 50 companies. He coaches based on his success in combining sound science with sophisticated technologies and applying their synergy to pivotal points in transforming markets. 

Bill isn’t the only Genoa Ventures affiliate at AACR this week! Our #portco Aqtual, Inc. will also be sharing new findings. Stay tuned for more! 

Genoa Ventures is a venture capital firm that specializes in investing in early-stage life sciences companies. The firm focuses on supporting innovative startups that are developing breakthrough technologies in the healthcare sector.

COM:GENOAVC

Genoa Ventures

Filings Not Available